The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

Gelijkaardige items

• Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
  door: Xu, Jianlin, et al.
  Gepubliceerd in: (2016)
• EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  door: Xu, Jianlin, et al.
  Gepubliceerd in: (2016)
• Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  door: Xu, Jianlin, et al.
  Gepubliceerd in: (2016)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
  door: Lou, Yuqing, et al.
  Gepubliceerd in: (2021)
• Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
  door: Zhang, Xueyan, et al.
  Gepubliceerd in: (2018)